Friedreich Ataxia Clinical Trial
Official title:
A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA)
The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale [mFARS]) and safety of vatiquinone in participants with Friedreich ataxia (FA).
During the double-blind, placebo-controlled phase, participants will be stratified by baseline mFARS score (<40 versus ≥40), age of disease onset (<14 versus ≥14), and age at screening (≤21 years or >21 years) and randomized to receive either vatiquinone or placebo using interactive response technology (IRT). Following completion of the randomized, double-blind, placebo-controlled phase (72 weeks), participants will enter into an open-label extension phase (24 weeks) during which they will receive open-label treatment with vatiquinone at the dose they received in the randomized phase of the study (for participants entering the extension phase who initially received placebo, the dose of vatiquinone will be determined based on age and weight) and then a safety follow-up (approximately 30 days [±5 days] after last dose or termination visit, whichever is later). The primary efficacy analysis will be based on change from baseline in mFARS score of participants between 7 and 21 years old. In order to explore the treatment efficacy and safety, approximately an additional 20 participants >21 years of age will be randomized for a total of approximately 126 participants. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05573698 -
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
|
Phase 1 | |
| Completed |
NCT00229632 -
Idebenone to Treat Friedreich's Ataxia
|
Phase 2 | |
| Completed |
NCT05579691 -
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
|
Phase 2 | |
| Completed |
NCT04273165 -
Safety and Efficacy of Etravirine in Friedreich Ataxia Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05874388 -
Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia
|
N/A | |
| Completed |
NCT02594917 -
Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension
|
||
| Completed |
NCT01716221 -
An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia
|
Phase 4 | |
| Active, not recruiting |
NCT05485987 -
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
|
Phase 2 | |
| Completed |
NCT03214588 -
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
|
Phase 2 | |
| Completed |
NCT03418740 -
Neurology Measures in FA Children
|
||
| Not yet recruiting |
NCT06054893 -
A Study of Omaveloxolone in Children With Friedreich's Ataxia
|
Phase 1 | |
| Recruiting |
NCT04921930 -
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03933163 -
Micronised Resveratrol as a Treatment for Friedreich Ataxia
|
Phase 2 | |
| Completed |
NCT02705547 -
Rosuvastatin (Crestor) in Friedreich Ataxia
|
Early Phase 1 | |
| Completed |
NCT02035020 -
A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients
|
Phase 2 | |
| Completed |
NCT00015808 -
Safety Study of Idebenone to Treat Friedreich's Ataxia
|
Phase 1 | |
| Completed |
NCT04817111 -
NAD+ Precursor Supplementation in Friedreich's Ataxia
|
Phase 2 | |
| Active, not recruiting |
NCT05168774 -
FRDA Investigator Initiated Study (IIS) With Elamipretide
|
Phase 1/Phase 2 | |
| Completed |
NCT03917225 -
A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
|
Phase 2 | |
| Completed |
NCT00224640 -
Iron-Chelating Therapy and Friedreich Ataxia
|
Phase 1/Phase 2 |